M&A Deal Summary |
|
|---|---|
| Date | 2016-03-07 |
| Target | Sanofi - Surgestone Provames Tredemine and Speciafoldine Rights |
| Sector | Life Science |
| Buyer(s) | Merus Labs International |
| Sellers(s) | Sanofi |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Sector | Life Science |
| Employees | 10 |
| Revenue | 36M USD (2015) |
Merus Labs International, Inc. is a specialty pharmaceutical company focused on acquiring and optimizing legacy and growth products. The Company leverages its expertise and scalable platform across Europe, Canada and select other markets to deliver value.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 2 of 2 |
| Country: France M&A | 1 of 1 |
| Year: 2016 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-02-01 |
UCB - Three Cardiovascular Products
Belgium UCB - Three Cardiovascular Products consists of Elantan®, Isoket® and Deponit® rights is a producer of medical products to treat both acute and chronic coronary artery disease. |
Buy | €92M |
| Category | Company |
|---|---|
| Founded | 1994 |
| Sector | Life Science |
| Employees | 82,878 |
| Revenue | 44.3B EUR (2024) |
Sanofi is a French multinational pharmaceutical company. Sanofi was founded in 1994 and is based in Paris, France.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 15 |
| Sector: Life Science M&A | 2 of 8 |
| Type: Divestiture M&A Deals | 4 of 15 |
| Country: France M&A | 3 of 9 |
| Year: 2016 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-02-03 |
Laboratoire Oenobiol S.A.S.
Paris, France Laboratoire Oenobiol S.A.S. produces, and supplies nutritional, health and beauty supplements. Oenobiol Solaire a nutritional supplement that protects the skin and favours a better suntan by activating melanin synthesis. Oenobiol supplements are scientifically approved products and are manufactured according to pharmaceutical standards. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-02-13 |
Sanofi SA - Consumer Healthcare Products
Paris, France Sanofi SA - Consumer Healthcare Products includes Prontalgine®, an analgesic for the treatment of moderate to severe pain, which has grown at double digit rates over the last four years and is available only in France. The portfolio also includes Buscopan®2, an antispasmodic; Suppositoria Glycerini3, a laxative; and Mucothiol® and Mucodyne®4, expectorants for cough and flu. |
Sell | €83M |
